This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

VERA presents a classic pre-binary-event asymmetry problem: with the stock already up 50% heading into the July 7 PDUFA date, the market is implicitly pricing in approximately 70-75% approval probability using simplified risk-neutral pricing. Running a basic expected value model — assuming +20% post-approval upside from current elevated levels versus -55 to -65% on a CRL — yields a negative EV of approximately -8% at current prices. The $200M institutional position adds credibility to the thesis but simultaneously creates a dangerous overhang: institutional profit-taking on approval news is a well-documented 'sell-the-news' mechanism. IgA nephropathy is a validated FDA space (Tarpeyo, Filspari, Fabhalta all approved), which improves base rates, but atacicept's TACI-Ig mechanism has nuanced safety profile questions the FDA may scrutinize. The asymmetry is structurally unfavorable for new longs at current levels. ⚡ DEEP SONNET: Post-July 7 decision only: on approval with immediate -10 to -15% 'sell-the-news' pullback to re-entry zone, or 6-8 weeks post-CRL washout if pipeline data supports long-term re-rating. Do NOT initiate new longs at current +50% elevated levels. | TP:18% SL:32% | 7-14 days around catalyst, then reassess Q3 2025 pipeline milestones | Risk:HIGH — Binary FDA event with demonstrably negative expected value at current price levels. Downside on CRL (-55 to -65%) materially outweighs limited upside on approval (+15 to +20%) given 50% pre-run compression. Concentrated single-fund position creates exit liquidity risk. Additional tail risk from FDA requesting label restrictions or REMS even on conditional approval. | Sizing:CONSERVATIVE